Phase 2 clinical study data showing retatrutide delays gastric emptying in humans. Measures gastric emptying rate with standardized scintigraphy or breath test in subjects treated with retatrutide. Demonstrates that the GLP-1R component of retatrutide's triple agonism contributes to weight loss through slowed gastric emptying and reduced appetite—the same mechanism that causes GI side effects (nausea, early satiety) seen with GLP-1 agonists.
Urva, Shweta; O'Farrell, Libbey; Du, Yu; Loh, Mei Teng; Hemmingway, Andrea; Qu, Hongchang; Alsina-Fernandez, Jorge; Haupt, Axel; Milicevic, Zvonko; Coskun, Tamer